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Introduction: Results from the Women’s Health Initiative clinical tri-
als demonstrated no increase in the risk of lung cancer in postmeno-
pausal women treated with hormone therapy (HT). We conducted a 
joint analysis of the Women’s Health Initiative observational study data 
and clinical trials data to further explore the association between estro-
gen and estrogen-related reproductive factors and lung cancer risk.
Methods: Reproductive history, oral contraceptive use, and post-
menopausal HT were evaluated in 160,855 women with known HT 
exposures. Follow-up for lung cancer was through September 17, 
2012; 2467 incident lung cancer cases were ascertained, with median 
follow-up of 14 years.
Results: For all lung cancers, women with previous use of estrogen 
plus progestin of less than 5 years (hazard ratio = 0.84; 95% confi-
dence interval = 0.71–0.99) were at reduced risk. A limited number 
of reproductive factors demonstrated associations with risk. There 
was a trend toward decreased risk with increasing age at menopause 
(p
trend
 = 0.04) and a trend toward increased risk with increasing num-
ber of live births (p
trend
 = 0.03). Reduced risk of non–small-cell lung 
cancer was associated with age 20–29 years at first live birth. Risk 
estimates varied with smoking history, years of HT use and previous 
bilateral oophorectomy.
Conclusions: Indirect measures of estrogen exposure to lung tissue, 
as used in this study, provide only weak evidence for an association 
between reproductive history or HT use and risk of lung cancer. More 
detailed mechanistic studies and evaluation of risk factors in con-
junction with estrogen receptor expression in the lung should con-
tinue as a role for estrogen cannot be ruled out and may hold potential 
for prevention and treatment strategies.
Key Words: Lung cancer, Hormone therapy, Reproductive history.
(J Thorac Oncol. 2015;10: 1004–1013)
In 2013, an estimated 110,110 women in the US were diag-nosed with lung cancer and 72,220 died from this disease.1 
There remains a gender gap in incidence rates with men hav-
ing higher rates than women, but with the declining incidence 
among men and the leveling off of incidence among women 
only recently, this gender difference is narrowing. The life-
time risk of developing lung cancer is 6.9% in both men and 
women.1
While approximately 90% of lung cancer deaths are 
attributable to cigarette smoking in men, only 75–80% of lung 
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cancer deaths in women are attributable to smoking.2 There 
has been considerable debate about differences in lung can-
cer occurrence and characteristics between men and women. 
Women are more likely to have adenocarcinomas of the lung 
(45.0%) than men (37.2%) and are more likely to have tumors 
with EGFR mutations.3 Women who never smoked are also 
more likely to develop lung cancer than men who have never 
smoked.4–7 However, the 5-year relative survival after a lung 
cancer diagnosis is better for women than for men (20.0% and 
15.4%, respectively).1 Taken together, male–female differ-
ences in lung cancer risk, tumor characteristics and outcome 
have fueled investigations into the role of estrogens in lung 
cancer risk and prognosis.
Epidemiologic studies of estrogen as a risk factor for 
lung cancer have focused on reproductive and estrogen use 
history. Findings have been inconsistent, with reports of 
increased and decreased risk associated with postmeno-
pausal hormone therapy (HT), oral contraceptive (OC) use, 
pregnancy, and menstrual history.8–31 The Women’s Health 
Initiative (WHI) clinical trials (CTs) data demonstrated that 
neither the use of estrogen plus progestin or estrogen alone 
was associated with lung cancer incidence.18,19 Taken as a 
whole, inconsistent findings across studies are likely due to 
a number of factors including variations in HT dosing over 
time and potential misclassification of exposures, however, 
they suggest a possible role for exogenous estrogens (i.e., HT, 
OCs) in the development of lung cancer.
We evaluated the role of reproductive factors and 
hormone use in determining risk of lung cancer in women 
from both the Women’s Health Initiative Observational 
Study and CTs.
METHODS
The Women’s Health Initiative
The WHI enrolled a geographically and ethnically 
diverse cohort of 161,808 postmenopausal women age 50–79 
years between October 1, 1993 and December 31, 1998 at 40 
centers across the United States. All participants provided 
informed consent. Women were enrolled in one of four ran-
domized CTs testing use of estrogen alone or estrogen plus 
progestin, calcium plus vitamin D (CaD), or low fat diet 
(dietary modification—DM) on several outcomes. In addi-
tion, the observational study (OS) enrolled women who pro-
vided detailed lifestyle and medical history and were followed 
for disease outcomes. Details of recruitment32 and baseline 
characteristics of study participants33 have been published 
previously. Reproductive history (age at first birth, number 
of pregnancies, age at menarche, age at menopause, bilateral 
oophorectomy), use of unopposed estrogens, estrogen plus 
progesterone, and/or OCs (never used, duration of use <5, 5–9, 
10–14, 15+ years) were collected at the baseline clinic visit by 
self-report. Current users of HT were defined as women using 
HT at baseline in the OS, or women using HT at baseline in 
the DM or CaD trials (who were not participating in the HT 
trial) or women assigned to HT use in the HT CT. Past users 
of HT were defined as women not using HT at baseline in the 
OS, DM, or CaD CTs but who had used HT in the past, women 
receiving placebo in the HT CT but who had used HT in the 
past, or women randomized to HT who used HT in the past 
and completed a wash out period before going on trial. Never 
users of HT were defined as women never using HT in the OS 
or non-HT CTs or women on the placebo arm of the HT CT 
who had never used HT before trial initiation. Therefore, any 
of the participants, even those enrolled in the HT CT and ran-
domized to HT, could have been defined as past users of HT.
The type of HT was classified as that reported at base-
line for all women except for those on the intervention arm 
of the HT CT, for whom the assigned HT was used. Duration 
of use was calculated from start of use to before baseline or 
randomization. Self-report of age at enrollment, education, 
income, smoking status (never smoked more than 100 ciga-
rettes, ever smoked more than 100 cigarettes), number of ciga-
rettes smoked per day (<5, 5–14, 15–24, 25–34, 35–44, 45+), 
years smoked (<5, 1–9, 10–19, 20–29, 30–39, 40–49, 50+), 
age started smoking in 5-year intervals, age quit smoking in 
5-year intervals, passive smoke exposure as a child and as an 
adult (home and work), alcohol intake, physical activity, diet 
and medical history were obtained at baseline.
Study participants were followed annually in the OS, 
and biannually through 2005 and annually thereafter in the 
CTs. At each follow-up, additional questionnaire data were 
obtained including self-report of cancer. Self-reports of can-
cer were confirmed by review of medical records and pathol-
ogy reports. As of September 17, 2012, 2467 lung cancers had 
been reported and centrally adjudicated. Of these, 2220 were 
classified as non–small-cell lung cancers (NSCLC), 236 were 
classified as small-cell lung cancers (SCLC) and 11 had miss-
ing histology.
Statistical Approach
The baseline subject questionnaire data, supplemented 
with data on lung cancer incidence, were used in the analysis. 
The primary objective of this study was to assess the asso-
ciation of reproductive history and use of OCs and HT, after 
adjustment for tobacco use and other known lung cancer risk 
factors, with risk of lung cancer among women. Two hundred 
fifty-seven women who reported a history of lung cancer on 
the baseline questionnaire were excluded. In addition, 696 
women who were enrolled in the WHI studies but for whom 
there was no follow-up information were also excluded, leav-
ing 160,855 women in this analysis, with 2467 incident cases 
of lung cancer.
Associations between reproductive and hormonal fac-
tors and lung cancer incidence were assessed using Cox 
regression models to compute adjusted hazard ratios (HRs) 
and 95% confidence intervals (CIs). Time to incident lung 
cancer was computed as days from randomization in the CTs 
or enrollment in the OS to the first diagnosis of lung can-
cer during follow-up. Otherwise, follow-up was censored at 
the last documented follow-up contact, death, or September 
17, 2012, whichever came first. Additional analyses were 
conducted, stratified by baseline smoking status (never, for-
mer, current) and in relation to risk by lung cancer histology 
(SCLC, NSCLC, and specific NSCLC subtypes). For the 
analyses of histology subtype, each subtype was treated as a 
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separate outcome and lung cancer cases of a different subtype 
were censored at the time of diagnosis.
Each baseline hormonal or reproductive factor was 
modeled separately in relation to disease outcome. Tests for 
trend were performed by modeling the continuous form of the 
variable if it was originally collected; otherwise, a linear trend 
was evaluated by modeling the integer-scored categorical vari-
able as a continuous variable. A set of covariates was selected, 
a priori, for adjustment of potential confounding, including 
age at enrollment/recruitment (continuous), race/ethnicity 
(white, black, other), education (less than high school, high 
school degree  or equivalent, education after high school, col-
lege degree or higher), US region (Northeast, South, Midwest, 
West), pack-years of smoking (never smoked, <5, 5 to <20, 
≥20), family history of cancer, personal history of asthma 
or emphysema, and body mass index (<25, 25 to <30, ≥30). 
The baseline hazard function in the Cox model was strati-
fied by age (5-year groups); HT trial randomization assign-
ment or study enrollment (active conjugated equine estrogen 
[CEE] plus medroxyprogesterone acetate, placebo CEE and 
medroxyprogesterone acetate, active CEE, placebo CEE, or 
not randomized), DM trial randomization (intervention, con-
trol, or not randomized), CaD trial, or OS enrollment; hyster-
ectomy status at baseline; and extension study participation.
Associations were evaluated in a multivariable model 
that included statistically significant covariates and risk fac-
tors. Several variables were not retained in the final multivari-
able model because their inclusion made no important changes 
to risk estimates or their interpretation. These included age at 
menarche, number of births, history of asthma, age at meno-
pause, years since menopause, duration of past OC use, and 
duration of prior unopposed estrogen use.
Statistical tests were two-sided, and p values less than 
0.05 were considered statistically significant. All analyses 
were performed using the SAS system, version 9.3 (SAS 
Institute, Cary, NC).
RESULTS
Table 1 presents the baseline characteristics of the 
160,855 women included in the analysis stratified by lung can-
cer status. In the entire cohort, 2467 lung cancers were diag-
nosed during follow-up. After adjustment for multiple factors 
(see “Methods” and footnote of Table 2), the only variables in 
which there was a statistically significant relation with lung 
cancer risk overall, and NSCLC specifically, included later 
age at first live birth and later age at menopause, both of which 
were associated with a reduced risk. Increasing time since 
menopause was associated with an increased risk (Table 2).
The only statistically significant findings with regard to 
hormone use were a reduction in risk associated with previ-
ous use of estrogen plus progestin of less than 5 years for all 
lung cancers (HR = 0.84; 95% CI = 0.72–0.98) and a simi-
lar reduction in risk associated with 5 to less than 10 years 
of any previous hormone use for NSCLC (HR = 0.84; 95% 
CI = 0.71–0.99). Little variation in risk in association with 
hormone use was seen for subtypes of NSCLC including 
adenocarcinomas, squamous cell carcinomas, large cell and 
associated subtypes, and other NSCLC or unspecified NSCLC 
TABLE 1.  Baseline Characteristics of WHI Participants by 
Lung Cancer Status
Noncases  
(N = 158,388)
Lung Cancer Cases 
(N = 2467)
pn (%) n (%)
Age group at screening (5 yr intervals)
  50–54 21,258 (13.4) 161 (6.5) <0.001
  55–59 31,470 (19.9) 330 (13.4) -
  60–64 36,432 (23.0) 567 (23.0) -
  65–69 34,456 (21.8) 745 (30.2) -
  70–74 24,284 (15.3) 485 (19.7) -
  75–79 10,488 (6.6) 179 (7.3) -
Race/ethnicity
  White 130,738 (82.5) 2198 (89.1) <0.001
  Black 14,328 (9.0) 152 (6.2) -
  Hispanic 6306 (4.0) 35 (1.4) -
  American Indian 692 (0.4) 10 (0.4) -
  Asian/Pacific Islander 4119 (2.6) 38 (1.5) -
  Unknown 2205 (1.4) 34 (1.4) -
Education
  Less than high school 8362 (5.3) 137 (5.6) <0.001
  High school diploma/GED 27,003 (17.0) 457 (18.5) -
  School after high school 59,552 (37.6) 1017 (41.2) -
  College degree or higher 62,280 (39.3) 841 (34.1) -
  Missing 1191 (0.8) 15 (0.6) -
US region
  Northeast 36,109 (22.8) 658 (26.7) <0.001
  South 41,024 (25.9) 582 (23.6) -
  Midwest 34,863 (22.0) 492 (19.9) -
  West 46,392 (29.3) 735 (29.8) -
Smoking status
  Never 80,649 (50.9) 382 (15.5) <0.001
  Past 65,320 (41.2) 1359 (55.1) -
  Current 10,363 (6.5) 691 (28.0) -
  Missing 2056 (1.3) 35 (1.4) -
Pack years of smoking (categorical)
  Never smoker 80,649 (50.9) 382 (15.5) <0.001
  <5 22,374 (14.1) 133 (5.4) -
  5 to <20 21,940 (13.9) 346 (14.0) -
  ≥20 27,791 (17.5) 1506 (61.0) -
  Missing 5634 (3.6) 100 (4.1) -
History of emphysema
  No 143,852 (90.8) 2090 (84.7) <0.001
  Yes 5363 (3.4) 220 (8.9) -
  Missing 9173 (5.8) 157 (6.4) -
History of asthma
  No 144,044 (90.9) 2193 (88.9) <.001
  Yes 12,224 (7.7) 245 (9.9) -
  Missing 2120 (1.3) 29 (1.2) -
Age at menarche
  <12 34,607 (21.8) 552 (22.4) 0.686
  12 41,186 (26.0) 632 (25.6) -
(Continued)
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(data not shown). There were no significant relations to risk 
of SCLC.
Table 3 reports the relation between reproductive fac-
tors and lung cancer risk after additional adjustment for 
all other reproductive and hormone use variables that were 
significant in any of the lung cancer analyses detailed in 
Table 2. The results by lung cancer histology are also pre-
sented in Table 3. This analysis showed that less than 5 
years of previous use of estrogen plus progestin was associ-
ated with decreased risk of lung cancer (HR = 0.84; 95% 
CI = 0.71–0.99). A similar risk estimate was noted for 
NSCLC and SCLC, although these findings did not reach 
statistical significance. There was also a statistically sig-
nificant decrease in NSCLC incidence among women with 
a later age at first birth (HR = 0.84; 95% CI = 0.73–0.98), 
and for all lung cancers, a trend toward decreased risk with 
increasing age at menopause (p
trend
 = 0.04) and a trend 
toward increased risk with increasing number of live births 
(p
trend
 = 0.03) was observed.
Multivariable modeling was conducted for smoking 
status strata as described above (Table 4). Bilateral oopho-
rectomy before enrollment was differentially associated with 
lung cancer risk; risk was increased in never smokers who 
Duration of previous unopposed estrogen use
  Nonuser 101,910 (64.3) 1555 (63.0) 0.055
  <5 years 20,931 (13.2) 361 (14.6) -
  5 to <10 years 11,168 (7.1) 149 (6.0) -
  10+ years 24,374 (15.4) 402 (16.3) -
  Missing 5 (0.0) 0 (0.0) -
Estrogen + progesterone use ever
  No 116,991 (73.9) 1937 (78.5) <0.001
  Yes 41,394 (26.1) 530 (21.5) -
  Missing 3 (0.0) 0 (0.0) -
Duration of previous estrogen + progestin use
  Nonuser 116,991 (73.9) 1937 (78.5) <0.001
  <5 years 20,921 (13.2) 237 (9.6) -
  5 to <10 years 11,239 (7.1) 129 (5.2) -
  10+ years 9232 (5.8) 164 (6.6) -
  Missing 5 (0.0) 0 (0.0) -
Body-mass index (kg/m2), baseline
  <25 55,070 (34.8) 974 (39.5) <0.001
  25 to <30 54,547 (34.4) 836 (33.9) -
  ≥30 47,386 (29.9) 632 (25.6) -
  Missing 1385 (0.9) 25 (1.0) -
Family history of cancer
  No 50,859 (32.1) 671 (27.2) <0.001
  Yes 100,480 (63.4) 1678 (68.0) -
  Missing 7049 (4.5) 118 (4.8) -
OC, oral contraceptive.
TABLE 1. (Continued)
Noncases  
(N = 158,388)
Lung Cancer Cases  
(N = 2467)
pn (%) n (%)
TABLE 1. (Continued)
Noncases  
(N = 158,388)
Lung Cancer Cases  
(N = 2467)
pn (%) n (%)
  13 45,625 (28.8) 685 (27.8) -
  >13 36,342 (22.9) 587 (23.8) -
  Missing 628 (0.4) 11 (0.4) -
Number of pregnancies
  None 14,596 (9.2) 211 (8.6) 0.002
  1 11,069 (7.0) 162 (6.6) -
  2 30,475 (19.2) 438 (17.8) -
  3 35,280 (22.3) 517 (21.0) -
  4 27,310 (17.2) 435 (17.6) -
  ≥5 38,895 (24.6) 695 (28.2) -
  Missing 763 (0.5) 9 (0.4) -
Number of live births
  None 18,803 (11.9) 286 (11.6) 0.103
  ≥5 23,204 (14.7) 396 (16.1) -
  1–2 53,367 (33.7) 777 (31.5) -
  3–4 62,062 (39.2) 994 (40.3) -
  Missing 952 (0.6) 14 (0.6) -
Age at first birth, yr (categories)
  Never preg/no term preg 18,803 (11.9) 286 (11.6) 0.003
  <20 20,065 (12.7) 379 (15.4) -
  20–29 92,716 (58.5) 1408 (57.1) -
  30+ 11,728 (7.4) 173 (7.0) -
  Missing 15,076 (9.5) 221 (9.0) -
Age at menopause
  <40 14,193 (9.0) 290 (11.8) <0.001
  40–50 51,635 (32.6) 918 (37.2) -
  50+ 76,655 (48.4) 1020 (41.3) -
  Missing 15,905 (10.0) 239 (9.7) -
Years since menopause
  <5 yrs 20,239 (12.8) 151 (6.1) <0.001
  5–9 yrs 26,996 (17.0) 278 (11.3) -
  10–14 yrs 29,424 (18.6) 441 (17.9) -
  15–19 yrs 25,464 (16.1) 441 (17.9) -
  ≥20 yrs 47,031 (29.7) 1007 (40.8) -
  Missing 9234 (5.8) 149 (6.0) -
Oral contraceptive use ever
  No 92,686 (58.5) 1521 (61.7) 0.007
  Yes 65,699 (41.5) 946 (38.3) -
  Missing 3 (0.0) 0 (0.0) -
Duration of OC use
  Nonuser 92,732 (58.5) 1524 (61.8) 0.023
  <5 years 36,324 (22.9) 512 (20.8) -
  5 to <10 years 14,922 (9.4) 212 (8.6) -
  10+ years 14,407 (9.1) 219 (8.9) -
  Missing 3 (0.0) 0 (0.0) -
Unopposed estrogen use ever
  No 101,910 (64.3) 1555 (63.0) 0.393
  Yes 56,475 (35.7) 912 (37.0) -
  Missing 3 (0.0) 0 (0.0) -
(Continued)
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TABLE 2.  Risk of Developing Lung Cancer in Relationship to Baseline Reproductive and Hormonal Factors in WHI Participants
All Lung Cancer  
(N = 2467)
NSCLC  
(N = 2220)
SCLC  
(N = 236)
Cases HR (LCI–UCI) p Cases
HR  
(LCI–UCI) p Cases
HR  
(LCI–UCI) p
Age at menarche
  <12 478 1.00 0.334 431 1.00 0.290 46 1.00 0.931
  12 518 0.91(0.80–1.03) - 466 0.90 (0.79–1.03) - 49 0.94 (0.62–1.41) -
  13 590 0.92 (0.82–1.04) - 532 0.92 (0.81–1.04) - 57 0.98 (0.66–1.45) -
  >13 501 0.96 (0.85–1.09) - 447 0.95 (0.83–1.09) - 50 1.03 (0.69–1.54) -
Parity
  Parous 1841 1.00 0.674 1647 1.00 0.958 185 1.00 0.202
  Nulliparous 240 0.97 (0.85–1.11) - 224 1.00 (0.87–1.16) - 16 0.71 (0.43–1.20) -
Number of live birthsa
  1–2 659 1.00 0.052 596 1.00 0.130 60 1.00 0.157
  3–4 842 1.06 (0.96–1.18) - 755 1.06 (0.95–1.18) - 83 1.09 (0.78–1.53) -
  ≥5 340 1.14 (1.00–1.31) - 296 1.11 (0.96–1.29) - 42 1.36 (0.91–2.03) -
Age at first birth, yr (categories)a
  <20 317 1.00 0.064 289 1.00 0.030 27 1.00 0.524
  20–29 1212 0.87 (0.76–0.99) - 1071 0.81 (0.70–0.93) - 136 1.55 (1.00–2.42) -
  30+ 141 0.85 (0.69–1.05) - 133 0.83 (0.67–1.03) - 8 0.87 (0.39–1.98) -
Age at menopause
  <40 253 1.00 <0.001 224 1.00 <0.001 28 1.00 0.482
  40–50 795 0.90 (0.77–1.04) - 706 0.89 (0.76–1.04) - 84 0.93 (0.59–1.45) -
  50+ 875 0.73 (0.62–0.85) - 795 0.73 (0.62–0.86) - 77 0.68 (0.42–1.10) -
Years since menopause
  <5 yrs 128 1.00 <0.001 120 1.00 <0.001 8 1.00 0.256
  5–9 yrs 245 1.05 (0.83–1.32) - 219 1.01 (0.79–1.28) - 25 1.59 (0.68–3.70) -
  10–14 yrs 374 1.17 (0.92–1.49) - 334 1.14 (0.89–1.47) - 40 1.62 (0.68–3.87) -
  15–19 yrs 378 1.24 (0.97–1.60) - 343 1.25 (0.96–1.62) - 32 1.29 (0.52–3.22) -
  ≥20 yrs 882 1.54 (1.20–1.98) - 785 1.52 (1.17–1.97) - 92 1.90 (0.77–4.68) -
Bilateral oophorectomy
  No 1636 1.00 0.185 1474 1.00 0.229 159 1.00 0.281
  Yes 409 0.91 (0.80–1.04) - 369 0.92 (0.80–1.06) - 36 0.79 (0.51–1.22) -
Duration of OC use
  Nonuser 1297 1.00 0.934 1170 1.00 0.908 122 1.00 0.407
  <5 years 433 0.98 (0.87–1.10) - 386 0.96 (0.85–1.09) - 43 1.06 (0.74–1.52) -
  5 to <10 
years
183 1.05 (0.89–1.23) - 165 1.04 (0.87–1.23) - 18 1.23 (0.74–2.07) -
  10+ years 178 0.98 (0.84–1.16) - 159 0.96 (0.81–1.14) - 19 1.25 (0.76–2.07) -
Duration of previous hormone use
  Nonuser 969 1.00 0.503 864 1.00 0.589 100 1.00 0.663
  <5 years 421 1.00 (0.89–1.12) - 378 0.99 (0.88–1.12) - 43 1.09 (0.76–1.58) -
  5 to <10 years 212 0.86 (0.74–1.01) - 188 0.84 (0.71–0.99) - 23 1.12 (0.69–1.80) -
 10+ years 489 0.93 (0.82–1.05) - 450 0.95 (0.83–1.08) - 36 0.76 (0.49–1.17) -
Duration of previous unopposed estrogen use
  Nonuser 1311 1.00 0.634 1178 1.00 0.768 127 1.00 0.510
  <5 years 306 1.08 (0.94–1.23) - 270 1.06 (0.92–1.23) - 36 1.27 (0.85–1.89) -
  5 to <10 
years
127 0.88 (0.72–1.07) - 112 0.86 (0.70–1.06) - 14 1.05 (0.58–1.91) -
  10+ years 347 0.94 (0.82–1.09) - 320 0.97 (0.83–1.13) - 25 0.72 (0.43–1.20) -
(Continued)
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had undergone bilateral oophorectomy (HR = 1.47; 95% 
CI = 1.00–2.16; p = 0.049) and decreased in current smok-
ers who had undergone the same procedure (HR = 0.68; 
95% CI = 0.51–0.90). The risk associated with this proce-
dure was intermediate in former smokers (HR = 0.92; 95% 
CI = 0.76–1.1; p
trend
 = 0.098). In addition, among current 
smokers only, women with five or more live births were at 
34% increased risk and women with 10 or more years of pre-
vious use of estrogen plus progestin were at 62% increased 
risk, but this trend in risk associated with duration of use 
was not statistically significant.
DISCUSSION
This study found no consistent contributions to lung 
cancer risk for a wide range of reproductive history mea-
sures. This is an area in which the epidemiologic literature 
has been inconsistent. Decades ago, studies of adenocarci-
noma of the lung reported that early age at menopause was 
associated with decreased risk,8 and nonsignificant increases 
in risk were associated with later age at menarche, surgical 
menopause or early menopause and hormone use.22 Other 
studies have reported no association between lung cancer 
risk and reproductive factors,12,27 increased risk associated 
with increased parity,28 or decreased risk with increasing age 
at first live birth.10 In cohort studies, adenocarcinoma risk 
was reduced with late menarche and increased with early 
age at menopause (including that resulting from bilateral 
oophorectomy particularly before age 40 years),16 and over-
all lung cancer risk was increased in women having five or 
more children, a finding we replicated only among current 
smokers, while decreased for women giving birth for the 
first time after age 30 years.31 Boggs et al.34 report nonsig-
nificant increased risk of lung cancer in African American 
women with a history of bilateral oophorectomy before age 
40 years and fewer than 2 years of hormone use. We found 
that bilateral oophorectomy was differentially associated 
with lung cancer risk; risk was increased in never smokers 
(HR = 1.47; 95% CI = 1.00–2.16; p = 0.049) and decreased 
in smokers (HR = 0.68; 95% CI = 0.51–0.90). These find-
ings need further exploration to untangle contributions from 
the underlying reason for bilateral oophorectomy, age at sur-
gery, hormone use before and after surgery, and timing of 
cigarette exposure. Overall, however, published work, like 
our study, does not support the idea that reproductive history 
independently contributes to lung cancer risk.
The epidemiologic literature is also inconsistent with 
regard to the role of hormone use (both HT and OCs) in 
lung cancer risk. The overall results presented here suggest 
that OC and HT use are not associated with risk of lung can-
cer. Only in current smokers do we find increased risk asso-
ciated with 10 or more years of estrogen plus progestin use. 
There have been several pooled or meta-analyses of meno-
pausal HT and risk of lung cancer that included many of the 
same studies.14,15,21,35 Of the 11 studies and over 220,000 par-
ticipants included in the analysis by Oh et al.14, the pooled 
estimate of relative risk for lung cancer associated with HT 
use was 0.87 (95% CI = 0.74–1.02), a nonstatistically sig-
nificant reduction in risk. Among cohort studies, the esti-
mated relative risk was 1.01 (95% CI = 0.74–1.38), while 
among case–control studies the estimate was 0.81 (95% CI 
= 0.68–0.97). Of the 11 studies included, one study reported 
increased risk,8 four studies reported no association,10,12,23,36 
and three studies reported decreased risk11,37,38 associated 
with HT use. Another meta-analysis of 25 studies showed 
an odds ratio (OR) of 0.91 (95% CI = 0.83–0.99) for the 
association between HT use and lung cancer risk,35 while a 
pooled analysis of six case–control studies reported an OR 
Duration of previous estrogen + progestin use
  Nonuser 1643 1.00 0.728 1470 1.00 0.643 165 1.00 0.809
  <5 years 199 0.84 (0.72–0.98) - 184 0.85 (0.72–1.00) - 15 0.76 (0.44–1.32) -
  5 to <10 years 112 0.84 (0.69–1.03) - 100 0.81 (0.66–1.01) - 12 1.22 (0.66–2.26) -
  10+ years 137 1.01 (0.85–1.22) - 126 1.02 (0.84–1.23) - 10 0.93 (0.48–1.80) -
Use of postmenopausal hormone therapy
  None 812 1.00 0.142 731 1.00 0.133 76 1.00 0.963
  Past users only 350 1.02 (0.90–1.16) - 313 1.01 (0.89–1.16) - 37 1.16 (0.77–1.75) -
  Current usersb 928 0.91 (0.81–1.03) - 835 0.91 (0.80–1.02) - 89 0.97 (0.66–1.45) -
Numbers in the body of the table are for women with no missing values for the covariate of interest and the adjustment variables. Histology information was missing for 11 
patients. Risk estimates were adjusted for age at screening (continuous), race/ethnicity, pack-years of smoking (categories), education, US region, history of emphysema, history 
of asthma, BMI, and family history of cancer; models were stratified by 5-year age group, baseline hysterectomy status, study type (OS or trial arm for clinical trial participants), 
and WHI extension study participation. P value is for trend if greater than two categories. Trend tests were based on the continuous form of the variable if originally collected 
as such.
aAmong parous women only
bIncludes hormone trial participants who had been nonusers or past users but were randomized to active E-alone or active E + P.
NSCLC, non–small-cell lung cancer; SCLC, small-cell lung cancer; HR, hazard ratio; LCI, 95% confidence interval lower limit; UCI, 95% confidence interval upper limit; BMI, 
body mass index; OC, oral contraceptive; WHI, Women’s Health Initiative.
TABLE 2. (Continued)
All Lung Cancer  
(N = 2467)
NSCLC  
(N = 2220)
SCLC  
(N = 236)
Cases HR (LCI–UCI) p Cases
HR  
(LCI–UCI) p Cases
HR  
(LCI–UCI) p
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of 0.77 (95% CI = 0.66–0.90).21 Several large cohort stud-
ies, including the WHI CTs, have reported no association 
between HT use and incidence of lung cancer.16–19 The study 
by Schwartz et al.12 is the only one to evaluate risk by estro-
gen receptor (ER) expression in the lung tumors. Decreased 
risk of ER-positive NSCLC was reported in postmenopausal 
women taking HT (OR = 0.42; 95% CI = 0.24–0.74), with 
no association seen for ER-negative tumors.12 The WHI 
did not include a determination of lung tumor ER recep-
tor expression so it was not possible to evaluate differential 
effects of hormone use in ER-positive versus ER-negative 
lung cancer.
While not a primary analysis topic for this study, an 
important note is that 55% of the lung cancers were diagnosed 
among former smokers. We estimated, based on the data avail-
able, that 69% of these former smokers had quit smoking 
more than 15 years before lung cancer diagnosis. This sug-
gests that there is a large population of longer term women 
former smokers at risk.
This study has several strengths including its pro-
spective nature and large sample size. The prospective 
design allowed for collection of exposure data before lung 
cancer diagnosis. However, there were also some limita-
tions. While the CT data provide the best opportunity for 
understanding the relation between HT use and lung can-
cer risk, only a small number of lung cancer cases devel-
oped in the CT arms. All study arms collected smoking 
dose and duration as categorical variables, and therefore 
did not allow for specific pack-years of exposure to be 
calculated. This may have resulted in residual confound-
ing within smoking category. The other limitation is not 
having tumor ER expression data. Estrogen exposure may 
TABLE 3.  Multivariable Model for Lung Cancer Risk in WHI Participants
Lung Cancer  
(N = 1713)
NSCLC  
(N = 1541)
SCLC  
(N = 167)
HR (LCI–UCI) pa HR (LCI–UCI) pa HR (LCI–UCI) pa
Parity
  Nulliparous 0.95 (0.77–1.16) 0.589 0.92 (0.75–1.14) 0.465 1.10 (0.53–2.28) 0.804
Number of live births
  1 - 2 1.00 (reference) 0.030 1.00 (reference) 0.094 1.00 (reference) 0.091
  3 - 4 1.10 (0.98–1.24) - 1.08 (0.96–1.23) - 1.25 (0.85–1.82) -
  ≥5 1.17 (1.00–1.36) - 1.13 (0.96–1.33) - 1.52 (0.95–2.41) -
Age at first birth
  <20 1.00 (reference) 0.426 1.00 (reference) 0.287 1.00 (reference) 0.521
  20–29 0.89 (0.77–1.03) - 0.84 (0.73–0.98) - 1.40 (0.88–2.23) -
  30+ 0.96 (0.77–1.20) - 0.94 (0.75–1.19) - 0.97 (0.42–2.26) -
Age at menopause
  <40 1.00 (reference) 0.042 1.00 (reference) 0.058 1.00 (reference) 0.435
  40–50 0.91 (0.77–1.08) - 0.91 (0.76–1.08) - 0.95 (0.57–1.61) -
  50+ 0.80 (0.64–1.00) - 0.80 (0.63–1.02) - 0.76 (0.37–1.58) -
Years since menopause
  <5 yrs 1.00 (reference) 0.275 1.00 (reference) 0.311 1.00 (reference) 0.705
  5–9 yrs 0.99 (0.76–1.27) - 0.97 (0.74–1.27) - 1.23 (0.48–3.15) -
  10–14 yrs 1.06 (0.80–1.39) - 1.03 (0.78–1.38) - 1.44 (0.53–3.87) -
  15–19 yrs 1.03 (0.76–1.40) - 1.04 (0.76–1.43) - 1.02 (0.34–3.09) -
  ≥20 yrs 1.19 (0.83–1.69) - 1.16 (0.80–1.68) - 1.54 (0.45–5.28) -
Bilateral oophorectomy
  Yes 0.90 (0.77–1.04) 0.147 0.91 (0.78–1.06) 0.211 0.73 (0.45–1.19) 0.210
Duration of previous estrogen + progestin use
Nonuser 1.00 (reference) 0.174 1.00 (reference) 0.146 1.00 (reference) 0.713
  <5 years 0.84 (0.71–0.99) - 0.85 (0.71–1.02) - 0.73 (0.40–1.36) -
  5 to <10 years 0.89 (0.71–1.10) - 0.85 (0.68–1.08) - 1.40 (0.72–2.71) -
  10+ years 0.93 (0.76–1.14) - 0.92 (0.75–1.14) - 1.07 (0.54–2.10) -
Full model includes parity, number of live births, age at first live birth, age at menopause, years since menopause, bilateral oophorectomy, and duration of previous estrogen + 
progestin use. Risk estimates were further adjusted for age at screening (continuous), race/ethnicity, pack-years of smoking (categories), education, US region, history of emphysema, 
history of asthma, BMI, and family history of cancer; stratified by age group, baseline hysterectomy status, trial, and WHI extension study participation. Women missing any of these 
data were excluded from the model.
ap value is for trend if greater than two categories. Trend tests were based on the continuous form of the variable if originally collected. Trends for number of live births and age at 
first birth are among parous women only.
BMI, body mass index; WHI, Women’s Health Initiative.
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differentially affect development and/or progression of 
tumors with specific characteristics. Hormone use data 
also may not accurately reflect local estrogen level in the 
lung and therefore null associations between hormone use 
and lung cancer risk should not rule out the potential for a 
role of estrogen in lung carcinogenesis. Multiple pathways 
of estrogen action exist39–48 and estrogen levels in lung tis-
sue, both from endogenous and exogenous estrogens, have 
never been measured, so the role of estrogen in lung cancer 
risk is still an open question.
In conclusion, this large, prospective study of lung 
cancer in women did not find strong associations with spe-
cific reproductive variables and risk, and provided only 
weak support for a role of hormone use in the etiology of 
lung cancer. There remain questions about estrogen and 
lung cancer risk that will not easily be answered by studies 
focusing on hormone use. The interplay among cigarette 
smoking, estrogen, genetic susceptibility, and lung cancer 
is complex and continued study is necessary to tease apart 
these relationships.
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  Nulliparous 1.13 (0.67–1.90) 0.650 0.83 (0.63–1.10) 0.204 1.09 (0.75–1.60) 0.652
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  40–50 1.43 (0.85–2.41) - 0.84 (0.67–1.05) - 0.95 (0.70–1.30) -
  50+ 1.11 (0.59–2.10) - 0.76 (0.57–1.03) - 0.82 (0.52–1.28) -
Years since menopause
  <5 yrs 1.00 (reference) 0.275 1.00 (reference) 0.311 1.00 (reference) 0.705
  5–9 yrs 1.03 (0.57–1.86) - 0.96 (0.66–1.39) - 0.87 (0.55–1.39) -
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  10+ years 1.31 (0.82–2.10) - 0.79 (0.60–1.04) - 1.62 (1.09–2.41) -
Full model includes parity, number of live births, age at first live birth, age at menopause, years since menopause, bilateral oophorectomy, and duration of previous estrogen + 
progestin use. Risk estimates were further adjusted for age at screening (continuous), race/ethnicity, pack-years of smoking (categories), education, US region, history of emphysema, 
history of asthma, BMI, and family history of cancer; stratified by age group, baseline hysterectomy status, trial, and WHI extension study participation. Women missing any of these 
data were excluded from the model.
ap value is for trend if greater than two categories. Trend tests were based on the continuous form of the variable if originally collected. Trends for number of live births and age at 
first birth are among parous women only.
BMI, body mass index; WHI, Women’s Health Initiative.
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